California State Teachers Retirement System Sells 29,358 Shares of Boston Scientific Corporation $BSX

California State Teachers Retirement System decreased its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 1.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,270,596 shares of the medical equipment provider's stock after selling 29,358 shares during the quarter. California State Teachers Retirement System owned 0.16% of Boston Scientific worth $96,909,037 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Kelleher Financial Advisors acquired a new stake in Boston Scientific during the 2nd quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of Boston Scientific during the 1st quarter worth about $28,000. Rakuten Securities Inc. bought a new position in shares of Boston Scientific in the second quarter worth about $30,000. Cassaday & Co Wealth Management LLC bought a new stake in shares of Boston Scientific during the first quarter valued at approximately $32,000. Finally, Cetera Trust Company N.A bought a new stake in shares of Boston Scientific during the 2nd quarter valued at $32,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Down 1.9%

Shares of NYSE:BSX traded down $0.86 during trading hours on Tuesday, hitting $44.19. 9,198,774 shares of the company's stock traded hands, compared to its average volume of 18,544,814. The business has a fifty day moving average price of $47.00 and a 200-day moving average price of $54.31. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $105.65. The firm has a market capitalization of $64.04 billion, a P/E ratio of 17.88, a price-to-earnings-growth ratio of 1.00 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. During the same period in the previous year, the firm posted $0.75 EPS. The business's revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts expect that Boston Scientific Corporation will post 3.29 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.

Insider Activity

In other Boston Scientific news, Director Edward Ludwig acquired 5,000 shares of the business's stock in a transaction on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David Habiger purchased 2,100 shares of the firm's stock in a transaction on Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company's stock, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on BSX. Robert W. Baird set a $56.00 target price on Boston Scientific in a research report on Thursday, July 30th. Needham & Company LLC decreased their price objective on Boston Scientific from $77.00 to $57.00 and set a "buy" rating on the stock in a report on Wednesday, July 8th. Raymond James Financial restated an "outperform" rating and set a $57.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Mizuho reduced their price objective on shares of Boston Scientific from $90.00 to $70.00 and set an "outperform" rating for the company in a research note on Wednesday, July 15th. Finally, Barclays dropped their price objective on Boston Scientific from $96.00 to $89.00 and set an "overweight" rating for the company in a report on Thursday, May 28th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $71.46.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.